19 completed, 2 terminated. 16 Phase 1, 5 Phase 2.
By phase and status
Follow BI 409306: new trials by email Literature Review of BI 409306 trials Research Report on BI 409306
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine
Lamotrigine, BI 409306, Placebo - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 40 | 2020-12-01 | 2024-03-12 |
This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)
BI 409306, Moxifloxacin, Placebo matching to BI 409306 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 47 | 2019-05-09 | 2024-03-12 |
This Study in Healthy Men and Women Tests How the Body Takes up BI 409306
BI 409306 (C-13/N-15), BI 409306 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 9 | 2018-04-27 | 2024-08-20 |
This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months
BI 409306, Placebo - Schizophrenia | Phase 2 | Terminated | Boehringer Ingelheim | 264 | 2017-12-07 | 2025-05-14 |
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
BI 409306, Placebo - Psychotic Disorders | Phase 2 | Terminated | Boehringer Ingelheim | 50 | 2017-09-29 | 2025-05-14 |
This Study Tests in Healthy Korean Women Which Effects BI 409306 and a Birth-control Pill Have on Each Other
Microgynon® 30, BI 409306 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 16 | 2017-06-29 | 2024-03-13 |
Drug-drug Interaction Trial Between Rifampicin and BI 409306 in Healthy Volunteers
BI 409306, Rifampicin - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 15 | 2017-05-30 | 2024-03-07 |
Influence of Fluvoxamine on the Pharmacokinetics of BI 409306
Fluvoxamine, BI 409306 - Powder for oral solution (PfOS), BI 409306 - film coated tablet - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 18 | 2016-08-25 | 2024-08-21 |
Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects
BI 409306, Donepezil - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 32 | 2016-01-15 | 2024-08-20 |
BI 409306 Cardiac Safety Trial in Healthy Volunteers
BI 409306, Placebo - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 20 | 2015-05-04 | 2024-10-26 |
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Placebo matching BI 409306 25 mg, Placebo matching BI 409306 50 mg, BI 409306 25 mg - Schizophrenia, Alzheimer Disease | Phase 1 | Completed | Boehringer Ingelheim | 61 | 2015-04-15 | 2024-04-19 |
BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
Placebo, BI 409306, Donepezil - Alzheimer Disease | Phase 2 | Completed | Boehringer Ingelheim | 329 | 2015-01-21 | 2018-11-14 |
Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo
BI 409306, Placebo - Alzheimer Disease | Phase 2 | Completed | Boehringer Ingelheim | 128 | 2015-01-15 | 2018-11-28 |
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.
BI 409306 100 mg QD, BI 498306 50 mg QD, Placebo - Schizophrenia | Phase 2 | Completed | Boehringer Ingelheim | 518 | 2014-11-10 | 2017-10-19 |
Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers
BI 409306, Itraconazole - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 25 | 2014-10-08 | 2024-04-25 |
Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy Volunteers
BI 409306 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 18 | 2014-09-04 | 2024-07-31 |
Safety and Tolerability of BI 409306 in Patients With Schizophrenia
Placebo, BI 409306 - Schizophrenia | Phase 1 | Completed | Boehringer Ingelheim | 40 | 2013-06-28 | 2024-04-25 |
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 409306
BI 409306, Placebo - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 40 | 2012-05-01 | 2024-03-08 |
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses
BI 409306, Placebo - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 83 | 2012-01-01 | 2024-03-08 |
Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP (Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers
BI 409306, Placebo - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 20 | 2011-12-01 | 2024-03-21 |
Showing 20 of 21. Sign in to see all of them.
Conditions studied
Schizophrenia (4) · Alzheimer Disease (3) · Psychotic Disorders (1)
Sponsors
Boehringer Ingelheim (21)
Countries
Germany (13) · United States (8) · Canada (5) · Belgium (3) · France (3) · South Korea (3) · United Kingdom (3) · Austria (2) · Italy (2) · Japan (2) · Netherlands (2) · Poland (2) · Portugal (2) · Spain (2) · Taiwan (2)
Results publications
PMID 30755255, PMID 39637767, PMID 28433500, PMID 28956335, PMID 29177699, PMID 33354862
NIH funding
2016 (3), 2014 (2), 2017 (2), 2015 (1), 2018 (1)